Valuation: IO Biotech, Inc.

Market Cap 43.81M 38.91M 36.39M 33.16M 62.43M 4.22B 63.29M 440M 170M 2.15B 164M 161M 6.9B P/E 2023
-0.95x
P/E 2024 -0.63x
Enterprise Value -14.31M -12.71M -11.88M -10.83M -20.39M -1.38B -20.67M -144M -55.65M -702M -53.71M -52.55M -2.25B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.69%
Yield 2023 *
-
Yield 2024 -
1 day+100.00%
Current month+100.00%
1 month+19,900.00%
3 months-96.72%
6 months-99.54%
Current year-99.97%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.7
1 year 0
Extreme 1.0E-6
1.23
3 years 0
Extreme 1.0E-6
2.79
5 years 0
Extreme 1.0E-6
17.88
10 years 0
Extreme 1.0E-6
17.88
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/10/2021
Compliance Officer 58 23/01/2023
Investor Relations Contact - 01/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
5/6/25 Free

Director

35,144 0.0533%
5/6/25 Free

Director

35,144 0.0533%
5/6/25 Free

Director

35,144 0.0533%
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%0.00%-99.94%-99.99% 14.39K
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.57%+1.98%+28.45%+21.60% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average +9.12%-0.47%+37.77%+128.73% 39.24B
Weighted average by Cap. -0.41%-0.32%+58.41%+146.02%

Financials

2023 2024
Net sales - -
Net income -86.08M -76.46M -71.5M -65.16M -123M -8.29B -124M -865M -335M -4.22B -323M -316M -13.56B -95.49M -84.82M -79.32M -72.28M -136M -9.19B -138M -960M -371M -4.68B -359M -351M -15.04B
Net Debt -141M -125M -117M -106M -200M -13.55B -203M -1.41B -547M -6.9B -528M -517M -22.16B -58.12M -51.62M -48.27M -43.99M -82.82M -5.6B -83.95M -584M -226M -2.85B -218M -213M -9.15B
Logo IO Biotech, Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Employees
80
Date Price Change Volume
01/10/26 USD 0.000200 +100.00% 38,493
30/09/26 USD 0.000100 0.00% 7,603
29/09/26 USD 0.000100 0.00% 2,394
25/09/26 USD 0.000100 -50.00% 1,100
24/09/26 USD 0.000200 0.00% 2,001

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IOBTQ Stock